期刊
JOURNAL OF INFECTION AND CHEMOTHERAPY
卷 23, 期 12, 页码 826-829出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jiac.2017.07.006
关键词
Adverse effect; Nivolumab; Pneumonia; Lung cancer; Interstitial lung disease
资金
- Ono Pharmaceutical
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Boehringer Ingelheim
- AstraZeneca
- Taiho Pharmaceutical
- Hisamitsu Pharmaceutical Co
- Eli Lilly
- Pfizer
- Merck Serono Co., Ltd
- Yakult Pharmaceutical Industry
Nivolumab has been associated with unique adverse events known as immune-related adverse events. Although interstitial lung disease (ILD) is a life-threatening immune-related adverse event, the risk of ILD during nivolumab treatment is unclear. In this report, we encountered three patients with stage IV non-small cell lung cancer with signs of lung obstruction caused by tumor-mediated compression on imaging who developed acute ILD within 10 days of commencing nivolumab treatment. The first case involved a 74-year-old Japanese female never-smoker, the second a 67-year-old Japanese female never-smoker, and the third a 75-year-old Japanese female current-smoker. The first patient was administered nivolumab as third-line chemotherapy, the second was administered nivolumab as fifth-line chemotherapy, and the third was administered nivolumab as second-line chemotherapy. Regardless of aggressive treatments for ILD, 2 of 3 patients died. The findings of these cases suggest that obstructive findings in the lungs, which easily cause infections, may be an important risk factor for nivolumab-induced ILD. (C) 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据